Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 4,250 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 4,250 shares of the stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $22.57, for a total value of $95,922.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Tuesday, May 28th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total value of $98,515.00.
• On Friday, May 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.50, for a total value of $22,500.00.
• On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.
• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.72, for a total value of $346,080.00.

Enliven Therapeutics Price Performance

ELVN stock traded down $0.67 on Monday, reaching $22.70. 351,338 shares of the company traded hands, compared to its average volume of 276,006. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $26.00. The company has a market cap of $1.07 billion, a P/E ratio of -11.76 and a beta of 1.11. The firm has a fifty day simple moving average of $21.77 and a 200-day simple moving average of $17.88.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. On average, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

ELVN has been the subject of several research reports. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Mizuho began coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price for the company. Finally, Robert W. Baird began coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective for the company.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Exchange Traded Concepts LLC boosted its stake in shares of Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after buying an additional 2,208 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Enliven Therapeutics by 17.8% in the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock worth $187,000 after buying an additional 2,041 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Enliven Therapeutics in the 4th quarter worth $66,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after buying an additional 1,029 shares during the last quarter. Finally, AJOVista LLC purchased a new position in shares of Enliven Therapeutics in the 4th quarter worth $28,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.